Overcoming Immunodominance by A Nanoparticle Adjuvant for Universal Influenza Vaccine Development 2255617
CDN nanoparticle adjuvants broadened antibody specificity, enhanced germinal center reactions, and promoted durable long-lived plasma cell formation, which overcomes the immunodominance of conventional vaccines and represents a promising approach for developing next-generation influenza vaccines with broader and longer...